RxDoctor Payments Data

Ryan Biggers, MD

Family Medicine · Midwest City, OKNPI 1194723395

Payments from drug & device makers

$2,799in general payments, 2019–2025

Across 151 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$678
  • Novo Nordisk$409
  • AstraZeneca$275
  • Lilly USA, LLC$219
  • Bayer$207
  • GSK$151
  • plus $861 from 18 others

What the payments were for

  • Food & beverage$2,799100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,799 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$251,388
Medicare patients
409
Services billed
4,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide130$160,336
FarxigaDapagliflozin Propanediol77$77,446
EliquisApixaban41$40,270
JardianceEmpagliflozin45$39,050
TrulicityDulaglutide24$32,542
JanuviaSitagliptin Phosphate27$30,523
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog77$27,033
RybelsusSemaglutide19$21,388
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$17,048
MyrbetriqMirabegron26$16,585
Xigduo XrDapaglifloz Propaned/Metformin11$15,402
XareltoRivaroxaban17$14,792
Nurtec OdtRimegepant Sulfate14$13,416
LinzessLinaclotide21$13,008
Lantus SolostarInsulin Glargine,hum.Rec.Anlog74$9,781

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$409$181,723149 claims
AstraZenecaFarxiga$275$77,44677 claims
PfizerEliquis, Nurtec Odt, Paxlovid$91$59,32076 claims
Boehringer IngelheimJardiance$136$39,05045 claims
Lilly USA, LLCTrulicity$219$32,54224 claims
GSKTrelegy Ellipta, Breo Ellipta$151$23,35631 claims
Astellas Pharma US IncMyrbetriq$18$16,58526 claims
AbbVieLinzess$678$13,00821 claims
Sumitomo Pharma America, Inc.Gemtesa$20$5,85712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Midwest City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →